Kexing Biopharm Co.,Ltd.(688136),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688136 Kexing Biopharm Co.,Ltd.

Closed 12-29 15:00:01

31.77

-0.35

-1.09%

High32.39	Low31.62	Vol2.96M
Open32.19	D1 Closing32.12	Amplitude2.40%
Mkt Cap6.39B	Tradable Cap6.39B	Total Shares201.00M
T/O94.63M	T/O Rate1.47%	Tradable Shares201.00M
P/B3.73	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688136","market":"SH","secType":"STK","nameCN":"Kexing Biopharm Co.,Ltd.","latestPrice":31.77,"timestamp":1766991601000,"preClose":32.12,"halted":0,"volume":2957037,"delay":0,"changeRate":-0.0109,"floatShares":200999999,"shares":200999999,"eps":0.624,"marketStatus":"Closed","change":-0.35,"latestTime":"12-29 15:00:01","open":32.19,"high":32.39,"low":31.62,"amount":94629000,"amplitude":0.024,"askPrice":31.78,"askSize":8,"bidPrice":31.77,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.624,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767058200000},"marketStatusCode":5,"adr":0,"adjPreClose":32.12,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766971800000,1766979000000],[1766984400000,1766991600000]],"highLimit":35.33,"lowLimit":28.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201257250,"isCdr":false,"pbRate":3.73,"roa":"--","peRate":50.913462,"roe":"6.66%","epsLYR":0.16,"committee":0.570861,"marketValue":6394000000,"turnoverRate":0.0147,"status":1,"afterMarket":{"amount":0,"volume":0,"close":31.77,"buyVolume":0,"sellVolume":0,"time":1766993638480,"indexStatus":"Closed 12-29 15:30:00","preClose":32.12},"floatMarketCap":6394000000},"requestUrl":"/m/hq/s/688136/wiki","defaultTab":"wiki","newsList":[{"id":"1128782685","title":"Kexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1128782685","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128782685?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:00","pubTimestamp":1765191621,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), recently received the \"Drug Clinical Trial Approval...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"1164311679","title":"Former Construction Bureau Deputy Director Ventures into Pharma, Kexing Biopharm's Major Shareholder Cashes Out 1 Billion Before IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1164311679","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164311679?lang=en_us&edition=fundamental","pubTime":"2025-11-24 18:21","pubTimestamp":1763979674,"startTime":"0","endTime":"0","summary":"When people hear \"Kexing,\" many first think of Sinovac Biotech (SVA.O), the global star pharmaceutical company that made a fortune with its COVID-19 vaccine. However, in the capital markets, there is...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2584606649","title":"Kexing Biopharm Seeks China Approval for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584606649","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584606649?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:06","pubTimestamp":1763427997,"startTime":"0","endTime":"0","summary":"Kexing Biopharm  is seeking approval from Chinese regulators for its share listing in Hong Kong, according to a Tuesday filing with the Shanghai bourse.The biotechnology products developer's listing is still subject to approval by regulators in Hong Kong and mainland China, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"1194507103","title":"Kexing Biopharm Co.,Ltd. (688136.SH): Keying Medicine Plans to Transfer 5% Stake via Inquiry","url":"https://stock-news.laohu8.com/highlight/detail?id=1194507103","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194507103?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:22","pubTimestamp":1763122929,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) disclosed a shareholder inquiry-based transfer plan. The participating shareholder, Keying Medicine, intends to transfer 10.0628 million shares, representing 5% of the company's total equity.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","688136","BK1161","BK1574","BK0239","09939","BK1515"],"gpt_icon":0},{"id":"2583508704","title":"BRIEF-Kexing Biopharm's Shareholder To Sell 5.0% Stake In Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508704","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508704?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:58","pubTimestamp":1763121517,"startTime":"0","endTime":"0","summary":"BRIEF-Kexing Biopharm's Shareholder To Sell 5.0% Stake In CoNov 14  - Kexing Biopharm Co Ltd 688136.SS:SAYS SHAREHOLDER PLANS TO SELL 5.0% STAKE IN CO VIA INQUIRY-BASED TRANSFERSource textFurther company coverage: 688136.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL4N3WQ0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2583350816","title":"Kexing Biopharm  Says Shareholder Plans to Sell 5.0% Stake in Co via Inquiry-Based Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583350816?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:58","pubTimestamp":1763121517,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL4N3WQ0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2581116073","title":"Kexing Biopharm Files for Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2581116073","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581116073?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:33","pubTimestamp":1762497186,"startTime":"0","endTime":"0","summary":"Kexing Biopharm  submitted documents for its planned initial public offering on the Hong Kong Stock Exchange, according to a Friday disclosure to the Shanghai bourse.The biopharmaceutical company intends to use the IPO proceeds for research and development, biosimilar drug screening and development, introduction of new pharmaceutical products, establishment of a marketing team, and working capital.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"1128910002","title":"Kexing Biopharm (688136.SH) Submits H-Share Listing Application to HKEX and Publishes Application Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=1128910002","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128910002?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:06","pubTimestamp":1762427176,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co., Ltd. (688136.SH) announced that on November 6, 2025, it submitted an application to The Stock Exchange of Hong Kong Limited (HKEX) for the issuance of H-shares and listing on the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2579646351","title":"Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at Cphi Frankfurt 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579646351","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579646351?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:10","pubTimestamp":1761909003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUA4ZZZFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2571718341","title":"Kexing Biopharm's Sorafenib Generic Receives Approvals in Egypt and Peru","url":"https://stock-news.laohu8.com/highlight/detail?id=2571718341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571718341?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:28","pubTimestamp":1759231703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUA6MKCBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"1190654790","title":"Kexing Biopharm Co.,Ltd. (688136.SH) Plans to Issue H Shares for Listing on Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=1190654790","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190654790?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:30","pubTimestamp":1759228224,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that to deepen the company's \"innovation + internationalization\" strategic layout, accelerate overseas business development, further enhance the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"1181034097","title":"Kexing Biopharm (688136.SH): Clinical Trial Registration Application for GB10 Injection Receives Regulatory Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1181034097","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181034097?lang=en_us&edition=fundamental","pubTime":"2025-09-29 17:40","pubTimestamp":1759138837,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has recently received an \"Acceptance Notice\"...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2569727723","title":"Kexing Biopharm Unit's Respiratory Tract Infection Drug Lands on China's Breakthrough Therapy List","url":"https://stock-news.laohu8.com/highlight/detail?id=2569727723","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569727723?lang=en_us&edition=fundamental","pubTime":"2025-09-24 14:04","pubTimestamp":1758693878,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration included Kexing Biopharm  unit Shenzhen Sinovac Pharmaceutical's recombinant human interferon a1b inhalation solution in its breakthrough therapy designation list, according to a Shanghai bourse filing on Wednesday.Drugs under the list are provided with priority resources for their development.The drug, which is currently in phase III clinical trials, is used to treat children with lower respiratory tract infections caused by respiratory syncytial virus.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"1144922497","title":"Kexing Biopharm (688136.SH): Human Interferon α-1b Inhalation Solution Included in Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=1144922497","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144922497?lang=en_us&edition=fundamental","pubTime":"2025-09-23 16:08","pubTimestamp":1758614922,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that the human interferon α-1b inhalation solution, independently developed by its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"1136531837","title":"Kexing Biopharm's Controlling Shareholder Raises 750 Million Yuan Through 30% Discount Sale, Likely Paving Way for Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1136531837","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136531837?lang=en_us&edition=fundamental","pubTime":"2025-09-19 17:21","pubTimestamp":1758273691,"startTime":"0","endTime":"0","summary":"Recently, Kexing Biopharm Co.,Ltd. disclosed the results of its latest shareholder inquiry transfer. Controlling shareholder Keyi Medical transferred 10.0628 million unrestricted tradable shares to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","HSTECH","HSCEI","07226","BK4614","YANG","BK0239"],"gpt_icon":1},{"id":"2567194040","title":"Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567194040","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567194040?lang=en_us&edition=fundamental","pubTime":"2025-09-15 10:43","pubTimestamp":1757904230,"startTime":"0","endTime":"0","summary":"Uni-Bio Science Group  said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm  to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","688136","00690","UNI.USD.HKCC","UNI.USD.CC","BK0239"],"gpt_icon":0},{"id":"1109803602","title":"Kexing Biopharm (688136.SH) Shareholder Keyi Pharmaceutical Plans Inquiry-Based Transfer of 5% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1109803602","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109803602?lang=en_us&edition=fundamental","pubTime":"2025-09-14 16:08","pubTimestamp":1757837295,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced a shareholder inquiry transfer plan. The participating shareholder in this pre-IPO inquiry-based share transfer is Shenzhen Keyi Pharmaceutical Holdings...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","09939","BK1574","BK1515","159938","688136"],"gpt_icon":0},{"id":"2567315844","title":"Kexing Biopharm  Says Major Shareholder Shenzhen Keyi Pharmaceutical Plans Sale of 5% Company Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2567315844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567315844?lang=en_us&edition=fundamental","pubTime":"2025-09-14 16:05","pubTimestamp":1757837136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250914:nL3N3V101D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2567158446","title":"BRIEF-Kexing Biopharm Says Major Shareholder Shenzhen Keyi Plans Sale Of 5% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2567158446","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567158446?lang=en_us&edition=fundamental","pubTime":"2025-09-14 16:05","pubTimestamp":1757837136,"startTime":"0","endTime":"0","summary":"BRIEF-Kexing Biopharm Says Major Shareholder Shenzhen Keyi Plans Sale Of 5% StakeSept 14  - Kexing Biopharm Co Ltd 688136.SS:SAYS MAJOR SHAREHOLDER SHENZHEN KEYI PHARMACEUTICAL PLANS SALE OF 5% COMPANY STAKESource textFurther company coverage: 688136.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250914:nL3N3V101D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2566218927","title":"Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®","url":"https://stock-news.laohu8.com/highlight/detail?id=2566218927","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566218927?lang=en_us&edition=fundamental","pubTime":"2025-09-12 17:28","pubTimestamp":1757669282,"startTime":"0","endTime":"0","summary":"Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai  in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL95x3Vt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239","00690","BK1161"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-12-14","address":"山东省济南市章丘区埠村街道创业路2666号","stockEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0556},{"period":"3month","weight":-0.1494},{"period":"6month","weight":-0.1635},{"period":"1year","weight":0.4729},{"period":"ytd","weight":0.4716}],"companyName":"科兴生物制药股份有限公司","boardCode":"AI0027","perCapita":"17102股","boardName":"医药制造业","registeredCapital":"20125万元","compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"survey":"　　科兴生物制药股份有限公司的主营业务是重组蛋白药物和微生态制剂的研发、生产、销售。公司的主要产品是依普定、赛若金、白特喜、常乐康。","serverTime":1767007515395,"listedPrice":22.33,"stockholders":"11768人(较上一季度增加25.03%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kexing Biopharm Co.,Ltd.(688136),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kexing Biopharm Co.,Ltd.(688136) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kexing Biopharm Co.,Ltd.,688136,Kexing Biopharm Co.,Ltd.股票,Kexing Biopharm Co.,Ltd.股票老虎,Kexing Biopharm Co.,Ltd.股票老虎国际,Kexing Biopharm Co.,Ltd.行情,Kexing Biopharm Co.,Ltd.股票行情,Kexing Biopharm Co.,Ltd.股价,Kexing Biopharm Co.,Ltd.股市,Kexing Biopharm Co.,Ltd.股票价格,Kexing Biopharm Co.,Ltd.股票交易,Kexing Biopharm Co.,Ltd.股票购买,Kexing Biopharm Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kexing Biopharm Co.,Ltd.(688136),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kexing Biopharm Co.,Ltd.(688136) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}